RA01 is novel drug product and a first line therapy for preventing nosocomial infections at ICUs.

Technology advantages

• Novel mechanism of action and target: temporary intracorporeal inhibition and specific removal of inhibitory anti-αGal antibodies.
• Immediate protection to patients admitted to ICU.
• High efficacy against high priority MDR Gram-negative bacteria (E. coli, P. aeruginosa, K. pneumoniae).
• Lack of toxicity and side effects in rodents and primates (90 days follow up, in-house studies).
• Dosage and route of administration already defined.
• No generation of antimicrobial resistance. RA-01 is a drug of indirect activity against pathogens.
• The synthetic process already defined: Low risk and costs for validating and scaling up the production.